Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
Data showing that the location of EGFR exon 20 insertion mutations impacts patients' responses to Spectrum's poziotinib could have implications for other EGFR inhibitors.
Takeda wins FDA approval for targeted lung cancer drug biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
By Syndicated Content
May 28, 2021 | 2:06 AM
(Reuters) â AstraZenecaâs top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on Friday.
The European Commission has approved the lung cancer drug as an add-on treatment for adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, the British drugmaker said.
The approval was based on positive results from a late-stage trial called ADAURA, which showed Tagrisso cut the risk of the tumour growing back in patients or death by 80%.